Universe of New Mexico Health Sciences Researches Hope Alzheimer’s Dementia.

In a new paper Published in Alzheimer’s & DementiaA TEAM LED by Kiran Bhaskar, Ph.D., Professor in the Department of Molecular Genetics & Microbiology in the Unm School of Medicine, Found That an Experimental Vaccine Genured A Robust IMMUST INSPONSE Both Mice and Non-Human Primates, Building on Earlier Research.

“Because we’ve shown efficacy in the non-human primate, I think that is suggesting to us it’s much closer to a clinical trial,” Bhaskar said, adding that he and his college Capitalists and the Alzheimer’s Association to Launch a Phase 1 Trial in Humans.

Tau is a naturally occurring protein that helps stabilize neurons, but when it undergoes a process called phosphorylation, its definitions and is ejected from neurons into the extraclalular space, Creating the tangles that are characteristic of alzheimer’s and other neurodegenerastic diseases.

There are several new FDA -Proved Treatments for Drugs that Reduce Levels of Amyloid Beta, Another Protein Implicated in Alzheimer’s Pathology, but they have only a modest a medest face The disease, leading many to wonder whicher targeting tau might be a better bet.

The active immunotherapy developed at unm generates antibodies that bind to pt181, a region of the altered tau protein that has been identified as an alzheimer’s bimarker. In a 2019 paper Published in npj vaccinesBhaskar and his colleagues reported that when the vaccine was given to Mice Bred to Express Pathological Tau, Thei Generated Antibodies, Reduced the Extent of the Tangles in Key Brain Struptures and Idea Performance on Tests to Gauge their Cognitive Disability.

The new paper expands on that findings. The vaccine Elicited a Strong Immune Response in Two Other Strains of Mice Bred to Develop Tau-Reu-Related Disease –one of Whoan Had a Human Tau Gene Inserted in Its Genome. In a collaboration with the university of california, davis, and the california National Primate Research Center, The vaccine was also administerred to macaques, primetes with immigates and brains are al Humans. They also showed a strong and duable immune response.

The Researchers also tested antibodies in the serum from the immunized monkeys on Samples of blood plasma drawn from people with mild coagnitive impairment, often a priorne Alzheimer’s Dementia, as well as the sera in brain tissue from people who had died from alzheimer’s, and found that they bound to the human version of the tau protein.

The vaccine was developed using a Virus-Like Particle (VLP) Platform Developed by Bryce Chaackerian and David Peabody, Bhaskar’s colleagues in Molecular Genetics & MCOBIOLOGY. Vlps are essentially viruses with dna have been removed, rendering them harmless. Snippets of Proteins – in this case pt181 –Can be attached to their surface, rendering them visible to immune cells on the lookout for invaders.

Vlp-based vaccines have been shown to create duble immunity, with one primary inoculation and two booster shoots, bhaskar said. They don’t require adjuvants – SUBSTANCES (Such as aluminum) administerred with a vaccine to enhance the immune response. They have also also been shown to be safe in humans.

Nicole maphis, ph.d., a postdoctoral researcher in the unm department of neurosciences, was the first author on bot of the vaccine papers. She said the collaboration with uc davis was critical for validating the vaccine’s efficacy.

“This was important because it extends our work in an animal model that is more similar to humans,” She said. “Mice don’t a human immune response, but these non-human primations, their immune response is much more similar to humans.”